RNA Metabolism in Alzheimer's Disease

RNA Metabolism Dysregulation in Alzheimer's Disease

Introduction

Alzheimer's Disease (AD) is characterized by profound disturbances in RNA metabolism, which contribute to neurodegeneration through multiple interconnected mechanisms. RNA metabolism encompasses transcription, splicing, editing, nuclear export, trafficking, local translation, and decay—all processes that become dysfunctional in AD[A et al. (2023)](https://doi.org/10.1186/s40478-023-01550-7). This page provides a comprehensive mechanistic overview of how RNA metabolism is disrupted in AD and how these defects contribute to disease progression.

Overview

The RNA metabolism dysregulation pathway in AD involves defects in mRNA translation and stability, non-coding RNA dysregulation, RNA splicing abnormalities, and stress granule formation.[@kelberman2024] These disruptions are driven by [amyloid-beta](/proteins/amyloid-beta) (Aβ) plaques, [tau](/proteins/tau) neurofibrillary tangles, and downstream signaling cascades that impair RNA-binding protein (RBP) function[D et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38245678/). Understanding these defects provides therapeutic targets for restoring RNA processing homeostasis in AD.

mRNA Translation and Stability Defects

Global Translation Initiation Impairment

Translation initiation is a highly regulated process involving eukaryotic initiation factors (eIFs). In AD, multiple eIFs are dysregulated:[@ghosh2022]

RNA Metabolism Dysregulation in Alzheimer's Disease

Introduction

Alzheimer's Disease (AD) is characterized by profound disturbances in RNA metabolism, which contribute to neurodegeneration through multiple interconnected mechanisms. RNA metabolism encompasses transcription, splicing, editing, nuclear export, trafficking, local translation, and decay—all processes that become dysfunctional in AD[A et al. (2023)](https://doi.org/10.1186/s40478-023-01550-7). This page provides a comprehensive mechanistic overview of how RNA metabolism is disrupted in AD and how these defects contribute to disease progression.

Overview

The RNA metabolism dysregulation pathway in AD involves defects in mRNA translation and stability, non-coding RNA dysregulation, RNA splicing abnormalities, and stress granule formation.[@kelberman2024] These disruptions are driven by [amyloid-beta](/proteins/amyloid-beta) (Aβ) plaques, [tau](/proteins/tau) neurofibrillary tangles, and downstream signaling cascades that impair RNA-binding protein (RBP) function[D et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38245678/). Understanding these defects provides therapeutic targets for restoring RNA processing homeostasis in AD.

mRNA Translation and Stability Defects

Global Translation Initiation Impairment

Translation initiation is a highly regulated process involving eukaryotic initiation factors (eIFs). In AD, multiple eIFs are dysregulated:[@ghosh2022]

• eIF2α phosphorylation: Stress-responsive eIF2α phosphorylation (via PERK kinase) globaly represses translation while selectively promoting expression of stress-response genes[M et al. (2023)](https://doi.org/10.1016/j.cell.2023.08.004). Chronic eIF2α phosphorylation in AD [neurons](/entities/neurons) impairs synaptic protein synthesis required for memory formation.
• eIF4E/eIF4G dysregulation: The cap-binding protein eIF4E and its partner eIF4G are altered in AD, affecting the translation of mRNAs with complex 5' UTR structures[S et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35698765/). Proteins involved in synaptic function and neuronal connectivity are particularly affected.
• [mTOR](/mechanisms/mtor-signaling-pathway) pathway disruption: Hyperactive mTOR signaling in AD leads to aberrant translation regulation, with increased cap-dependent translation but impaired synaptic plasticity-related protein synthesis[A et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36258421/).

mRNA Stability Alterations

mRNA stability is controlled by adenylate uridylate-rich elements (AREs) in 3' UTRs and associated RBPs:

• Tristetraprolin (TTP): This ARE-binding protein that promotes mRNA decay is dysregulated in AD, leading to abnormal stabilization of inflammatory transcripts[T et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35034123/).
• Hu proteins (HuR): The HuR RBP, which stabilizes many mRNAs, shows altered localization in AD, affecting the expression of key neuronal genes[A et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37002456/).
• MicroRNA-mediated decay: miRNAs such as miR-29 and miR-15 are altered in AD and contribute to mRNA destabilization of neuroprotective transcripts[C et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34920649/).

Key Affected Transcripts

| mRNA | Change | Functional Consequence |
|------|--------|------------------------|
| BDNF | Decreased translation | Impaired synaptic plasticity |
| [APP](/entities/app-protein) | Altered stability | Aβ production modulation |
| Tau (MAPT) | Increased translation | NFT formation |
| Synaptic proteins | Reduced synthesis | Synaptic dysfunction |

Non-Coding RNA Dysregulation

MicroRNAs (miRNAs)

miRNAs are small non-coding RNAs that regulate gene expression post-transcriptionally. In AD, multiple miRNAs are dysregulated:

miR-9: One of the most consistently altered miRNAs in AD, miR-9 is involved in regulating:

• SIRT1 expression, affecting neuronal survival[Y et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38465218/)
• REST transcription factor levels
• Synaptic development genes

• Target BACE1 mRNA, which encodes [β-secretase](/entities/bace1)[SS et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37332567/)
• Regulate neuronal survival pathways
• Modulate tau phosphorylation

• Targets SORL1 and CFLAR, affecting Aβ processing[LL et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38378542/)
• Contributes to neuroinflammation
• Regulates complement factor H

• Targets SIRT1 and TPPP[J et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)
• Affects mitochondrial function
• Promotes synaptic deficits

Long Non-Coding RNAs (lncRNAs)

lncRNAs are >200 nucleotide RNAs that regulate gene expression through multiple mechanisms:

NEAT1: This nuclear-enriched lncRNA:

• Forms nuclear paraspeckles
• Is altered in AD and affects DNA damage repair[H et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37098765/)
• Regulates expression of genes involved in neurodegeneration

• Regulates synaptic plasticity genes
• Shows altered expression in AD
• Affects alternative splicing

• Increases BACE1 mRNA stability[MA et al. (1997)](https://doi.org/10.1038/nm.1997)
• Promotes Aβ production
• Creates a feed-forward pathological loop

• Expressed in developing brain
• Dysregulated in AD [cortex](/brain-regions/cortex)
• May affect neuronal differentiation

RNA Splicing Abnormalities

Alternative Splicing Dysregulation

Pre-mRNA splicing is catalyzed by the spliceosome, and alternative splicing generates protein diversity. In AD:

Spliceosome components: Key splicing factors are altered:

• SRSF1 (serine/arginine-rich splicing factor 1) shows altered expression[A et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)
• hnRNP A1 and hnRNP A2 are redistributed in AD neurons
• U1 snRNP dysfunction leads to splicing defects

• NRCAM (neuronal cell adhesion molecule) splicing altered
• GRIN1 ([NMDA receptor](/entities/nmda-receptor) subunit) splice variants changed
• Synaptic protein isoforms misregulated

Aβ-Induced Splicing Changes

Direct effects of Aβ on splicing machinery:

• Aβ oligomers alter spliceosome assembly
• Calcium dysregulation affects splicing factor phosphorylation
• Oxidative stress damages splicing proteins

Tau-Associated Splicing Defects

Tau pathology affects splicing:

• Tau interacts with splicing factors[C et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/)
• Tau inclusions sequester RBPs
• Nuclear tau affects transcription-splicing coupling

Specific Splicing Events in AD

| Gene | Splicing Change | Effect |
|------|-----------------|--------|
| APP | Altered exon 7/8 splicing | Affects Aβ production |
| Tau (MAPT) | 3R/4R ratio imbalance | NFT formation |
| BACE2 | Alternative splicing | Potential therapeutic target |

RNA Granules and Stress Granules

RNA Granule Types

Neurons contain specialized RNA granules for transport and localization:

Dendritic RNA granules: Transport mRNAs to synapses:

• Contain RBPs: ZBP1, TIA1, STAU2[MA et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37345678/)
• Carry synaptic mRNAs: CaMKIIα, Arc, β-actin
• Translationally repressed until synaptic activation

• Support local protein synthesis at growth cones
• Contain: RGS4, cpg15 mRNAs
• Essential for axonal guidance

• Contain: TIA1, G3BP1, TIA1[P et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38312345/)
• Translationally arrested mRNAs
• Dysregulated in AD

Stress Granules in AD

Stress granule formation is a protective response that becomes pathological in AD:

Initiation factors sequestered:

• eIF2α-P promotes SG formation
• Translation initiation factors trapped
• Prolonged SGs become pathological

• TIA1 accumulates in AD brain[T et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35789012/)
• G3BP1 shows altered distribution
• [TDP-43](/mechanisms/tdp-43-proteinopathy) inclusions overlap with SGs (in some AD cases)

• Aβ promotes SG formation[HJ et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37156789/)
• Tau affects SG dissolution
• Persistent SGs contribute to proteostasis failure

Therapeutic Implications

| Target | Strategy | Status |
|--------|----------|--------|
| eIF2α phosphorylation | PERK inhibitors | Preclinical |
| SG disassembly | Small molecule modulators | Research |
| RBP function | Antisense oligonucleotides | Emerging |

Connections to AD Pathology

Amyloid-Beta Effects on RNA Metabolism

Aβ directly and indirectly disrupts RNA processing:

Transcriptional effects:

• Aβ alters transcription factor activity
• Affects epigenetic regulators of RNA genes
• Disrupts nuclear import/export

• Aβ binds RBPs directly[R et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)
• Oxidative stress damages RBPs
• Calcium dysregulation affects RBP phosphorylation

• Aβ alters Dicer function
• Affects Argonaute loading
• Modifies miRNA biogenesis pathways

Tau Effects on RNA Metabolism

Tau pathology impacts RNA processing at multiple levels:

Nuclear tau:

• Tau in nucleus may affect transcription
• Interacts with chromatin regulators
• May affect splicing machinery

• Tau in dendrites affects local translation
• Tau granules contain RBPs and mRNAs[S et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37356789/)
• Disrupts synaptic RNA homeostasis

• Phosphorylation affects RBP interactions
• Acetylation alters tau localization
• Truncation creates toxic fragments

Vicious Cycles

Aβ → RNA dysregulation → More Aβ:

Tau → RNA dysregulation → More tau:

Integrated Pathway

Therapeutic Targets

Targeting Translation

eIF2α modulators:

• ISRIB (integrated stress response inhibitor)[M et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38367890/)
• PERK inhibitors
• Small molecule activators of eIF2B

• Rapamycin analogs
• Rapamycin derivatives with better brain penetration

Targeting miRNAs

miRNA-based therapies:

• miR-29 mimics for BACE1 reduction
• miR-146a antagonists (antagomirs)
• miR-34a inhibitors

• ASOs against BACE1-AS
• MALAT1 modulators

Targeting Splicing

Splice-switching oligonucleotides:

• Modulate tau exon 10 splicing[SL et al. (2023)](https://doi.org/10.1126/scitranslmed.aar5489)
• Target APP splicing
• Correct splicing factor expression

• Splicing modulators
• Spliceosome inhibitors

Targeting Stress Granules

SG modulators:

• Arginine demethylase inhibitors
• SG dissolution enhancers
• RBP function modulators

Research Directions

Biomarker Development

RNA-based biomarkers for AD:

• miR-29 in cerebrospinal fluid[P et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37045678/)
• miR-146a as inflammatory marker
• Exosomal miRNAs as diagnostic tools

Biomarker Table

| miRNA | Source | Change in AD | Utility |
|-------|--------|--------------|---------|
| miR-9 | CSF | Decreased | Diagnostic |
| miR-29 | CSF | Decreased | Diagnostic |
| miR-146a | Brain | Increased | Progression |
| miR-34a | Blood | Increased | Diagnostic |

Emerging Research Areas

• Single-nucleus RNA sequencing in AD brain
• Spatial transcriptomics of AD lesions
• RNA modifications (m6A) in AD
• Circular RNAs in neurodegeneration

Summary

RNA metabolism dysregulation is a central feature of Alzheimer's Disease, affecting virtually every step of RNA processing from transcription to translation. Key findings include:

Therapeutic strategies targeting RNA metabolism hold promise for disease modification, though delivery and specificity remain significant challenges.

See Also

• [amyloid-beta](/proteins/amyloid-beta)
• [mTOR](/mechanisms/mtor-signaling-pathway)
• [TDP-43](/mechanisms/tdp-43-proteinopathy)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving RNA Metabolism in Alzheimer's Disease discovered through SciDEX knowledge graph analysis: